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Summary
Objective: Marathon runners have an increased risk of developing joint disease. During and after a 42-km run, elevation of multiple cytokines
occurs in the blood, reflecting inflammatory processes. We compared this cytokine response with serum levels of cartilage oligomeric matrix
protein (COMP) and melanoma inhibitory activity (MIA), two markers for joint metabolism and/or damage.
Methods: Serum from eight endurance-trained runners was collected shortly before the start of a marathon run, after 31 km, 42 km, 2 h after
the end, on the first and on the second morning after the run. For comparison, serum was obtained from 35 healthy controls and 80 patients
with knee joint injury, rheumatoid arthritis or osteoarthritis. Serum levels of C-reactive protein (CRP), interleukin-1 (IL-1), interleukin-1
receptor antagonist (IL-1RA), interleukin-6 (IL-6), tumor necrosis factor- (TNF-), soluble interleukin-6 receptor (sIL-6R, gp80), soluble
tumor necrosis factor receptor II (sTNFRII, p75), COMP and MIA were measured by ELISA.
Results: Compared with healthy controls, the runner’s baseline serum levels of TNF-, sIL-6R, COMP and MIA were significantly increased.
COMP and MIA levels, higher than the upper normal limits of 5 g/ml and 6 ng/ml respectively, were found in seven and five of eight runners.
The elevated levels of COMP were similar to those found in joint injury or osteoarthritis, and the elevated levels of MIA were comparable to
those reported in rheumatoid arthritis. During the run, the serum levels of IL-1RA, IL-6, TNF- and COMP rose significantly, and gradually
returned to baseline within 24 h. Only modest changes of CRP, sIL-6R, sTNFRII and MIA occurred during the run. Late elevations of CRP
and MIA were observed after 24 and 48 h. The correlation analysis suggests associations between COMP, sIL-6R, TNF-, IL-1RA on one
hand and sTNFRII, and MIA and CRP on the other hand.
Conclusions: Elevated baseline levels of COMP and MIA might reflect increased joint matrix turnover and/or damage due to prior extreme
physical training. During the run, COMP was increasing possibly due to the severe physical strain on joint structures, associated with the
early inflammation. After the run, MIA and CRP increased within 24 h, suggesting a correlation with later inflammatory processes. Thus, our
data suggest that COMP and MIA are markers for distinct aspects of joint metabolism and/or damage in both disease and sport. © 2000
OsteoArthritis Research Society International
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Chondrocytes interact with various components of the
articular cartilaginous matrix. One of these macromol-
ecules is the 524 kDa pentameric glycoprotein called carti-
lage oligomeric matrix protein (COMP).1,2 In humans,
COMP is produced in articular cartilage by chondrocytes,
and in tendon, meniscus, and synovial tissue by
fibroblasts.3–6 In synovial fluid, increased amounts of
COMP have been reported after knee injury, in early stages
of osteoarthritis (OA), and in active reactive arthritis.7,8 In
contrast, in patients with advanced destruction of joints due
to rheumatoid arthritis (RA) or reactive arthritis, COMP is
decreased.3,9 The COMP fragmentation pattern in synovial
fluid appears to be a potential diagnostic marker for RA.222These fragments appear by enzymatic degradation of
cartilage mediated by serine proteases and matrix metallo-
proteinases.3,10 In serum, elevated levels of COMP occur
in knee trauma, early stages of OA, RA and in reactive
arthritis.3,8,9,11–13 Interestingly, in patients with knee injury,
a subgroup showed persistently elevated serum levels
of COMP.13 These patients, particularly those with auto-
antibodies against COMP, appear to have an increased risk
of developing post-traumatic OA.
Recently, an 11 kDa protein called melanoma inhibitory
activity (MIA) has been purified from metastatic melanoma
cell line supernatants.14 In malignancies, elevated serum
levels of MIA are predominantly found in metastatic
melanoma and to a lesser extent in ovarian, pancreatic and
breast cancer,15 whereas in non-malignant tissues, MIA
production is predominantly found in cartilage.16,17 Highly
elevated serum levels of MIA were also found in patients
with RA, associated with positive rheumatoid factors and
joint destruction.18.
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joint disease.19 Erosive joint lesions can frequently be
observed.20,21 In the ankle, degenerative changes of the
calcaneous tendon, tendosynovitis of the flexor hallucis
longus, joint effusions and cartilage damage have been
detected by magnetic resonance tomography.22 An inten-
sive cytokine response [i.e., interleukin-1 receptor antagon-
ist (IL-1RA), interleukin-6 (IL-6), and tumor necrosis
factor- (TNF-)] occurs during and/or after prolonged
running.23–26 The intensive training and the run itself
induce inflammation and muscle fiber necrosis which is
reflected in rhabdomyolysis and myoglobinuria.27 Many
changes may simply reflect extreme training and the effects
of repetitive strain on soft tissue and cartilagenous struc-
tures. It is difficult, however, to differentiate between pri-
mary cartilage damage and secondary inflammation. We
compared the serum levels of COMP and MIA between
marathon runners, non-running healthy subjects and
patients with various joint diseases, and we examined
whether they can be used as markers for joint metabolism
in sport medicine. In addition, the kinetics of COMP and
MIA concentrations in serum before, during and after the
run were compared with levels of markers for inflammation,
i.e., C-reactive protein (CRP), circulating cytokines
(interleukin-1 (IL-1), IL-1RA, TNF-, and IL-6) and
soluble cytokine receptors (interleukin-6 receptor gp80
(sIL-6R), and tumor necrosis factor type II p75 (sTNFRII),
the most specific receptor for TNF-). Some of these
systemic cytokines are known to be increased during
marathon running (TNF-, IL-6), while other markers may
reflect counter-regulatory mechanisms (IL-1RA, soluble
receptors). We investigated whether this systemic
response is associated with changes in two markers of joint
metabolism (COMP and MIA).Materials and methods
Serum from eight endurance-trained runners (25 to 34
years old) was obtained from the participants of a non-
competitive marathon, in whom the metabolic influence of a
protein-supplemented carbohydrate drink was studied by
other investigators.28 Since there was no treatment differ-
ence for the parameters discussed in the present study,
only the control trial data from each runner are presented
here. Daily conditioning exercise was allowed, but the
athletes did not run for at least 3 weeks before the test.
Blood samples were collected from an antecubital vein, at
the same arm at all times points: shortly before the start of
the run (T0), after 31 km (T1), after 42 km (T2), 2 h after the
end of the run (T3), on the first (T4) and on the second
morning (T5) after the run. The running time in this non-
competitive marathon ranged from 3 h 02 min to 3 h
48 min. At the end of the run, no signs of dehydration was
detectable. No physical activity was allowed for 2 days after
the run. Serum were also obtained from non-running
healthy volunteers (N=35; 16 controls who had never run in
any competitive race were age-and sex-matched and used
for statistical purposes). In addition, serum was also drawn
from patients with knee joint injury (N=30),13 RA (N=30)
and OA (N=20). RA and OA patients fulfilled the criteria of
29,30the American College of Rheumatology.C-REACTIVE PROTEIN AND CYTOKINES
Serum levels of CRP (Eurogenetics CRP, Tenssenderlo,
Belgium), TNF-, IL-6 (Coaliza TNF- and IL-6, KabiDiagnostica AB, Mo¨lndal, Sweden), IL-1, IL-1RA, sIL-6R
gp80, and sTNFRII p75 (Quantikine IL-1 HS, IL-1RA,
sIL-6R and sTNFRII, R&D Systems, Abingdon, United
Kingdom) were evaluated by ELISA using commercially
available kits. The cut-off of ‘normal’ serum level of CRP
was established by use of 80 sera from healthy donors.CARTILAGE OLIGOMERIC MATRIX PROTEIN
Serum levels of COMP were measured by competitive
ELISA as previously described.3 Briefly, microtiter plates
were coated with 1 g/ml purified human COMP diluted in
phosphate buffered saline (PBS), kept overnight at 4°C and
blocked with 1% bovine serum albumin (BSA, Sigma, St.
Louis, MO, U.S.A.) in PBS for 2 h at 22–24°C. In a separate
plate, serum was diluted in PBS (1:10 to 1:40). The
samples were preincubated with an equal volume of rabbit
polyclonal antiserum overnight at 4°C. The solutions were
transferred to the coated plates and incubated for 1 h at
22–24°C. The plates were washed with PBS containing
0.05% Tween-20 (Merck, Dietikon, Switzerland). The
bound anti-COMP antibodies were incubated with horse-
radish peroxidase (HRP)-conjugated swine anti-rabbit IgG
(Dako, Zug, Switzerland), diluted 1:200 in PBS with 1%
BSA, for 1 h at 22–24°C. The wells were washed and
bound antibodies were visualized by means of 0.25 mg/ml
5-amino-2-hydroxy benzoic acid (Sigma), pH 6.0, as sub-
strate, in the presence of 0.00024% H2O2. The reaction
was stopped with 2 N NaOH and the absorbance was read
at 490 nm. Standardization was performed with COMP
derived from human articular cartilage.MELANOMA INHIBITORY ACTIVITY
Serum levels of MIA were determined by sandwich
ELISA as previously described.15 Briefly, two monoclonal
antibodies directed against 14-meric NH2-terminal and
COOH-terminal peptides (monoclonal antibodies 1A12 and
2F7, Boehringer Mannheim, Germany) were conjugated to
HRP and biotin, respectively. Ten l of serum or MIA
standards were incubated with 200 l reagent contain-
ing HRP-1A12 and biotinylated-2F7 antibodies in a
streptavidin-coated microtiter plate for 45 minutes with
continuous shaking. After washing three times in PBS,
200 l of 2,2′-azino-di-(3)-ethylbenz-thiazoline sulfonate
(Boehringer Mannheim) was added to the wells and
absorbance was measured at 405 nm. Standardization
was performed with MIA derived from transfected Chinese
hamster ovary cells.STATISTICS
Inter- and intra-assay variation and limits of sensitivity for
COMP and MIA have been reported previously.3,15 In our
study, COMP and MIA serum concentrations were com-
pared between matched controls and baseline levels in
runners (T0), by means of the Mann-Whitney U-test (SPSS
8.0). Concentration changes over the course of time (T0 to
T5) were evaluated with the Wilcoxon matched pair test.
Mutual relationships among variables were established
using Spearman’s rank correlation coefficients. P-values
<0.05 were considered as significant.
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Compared with 16 age- and sex-matched controls,
serum levels of CRP in marathon runners were not
increased before (T0), during (T1, T2) nor immediately after
the run (T3) (Fig. 1). On the other hand, CRP increased
significantly within 24 h (T4) and remained elevated after
48 h (T5) (P<0.001 for both times, compared with either
controls or T0). At T4, four of eight runners showed CRP
levels higher than the upper normal limit of 5 g/ml.INTERLEUKIN-1 AND INTERLEUKIN-1 RECEPTOR ANTAGONIST
Concentrations of 0.2 to 9.1 pg/ml IL-1 and 85 to
490 pg/ml IL-1RA were measured in the serum of 35
healthy individuals. Regarding the 16 matched controls,
medians were 1.9 pg/ml and 110 pg/ml, respectively (Fig.
2). In marathon runners, no significant difference was found
for the serum levels of IL-1, before, during or after the run.
In contrast, a significant but transient increase of IL-1RA
occurred during the run. At T0, the median level of IL-1RA
was similar in runners (95 pg/ml) and controls, whereas the
medians at T1, T2 and T3 reached significantly higher
values: 260, 485 and 1195 pg/ml (P<0.001, compared with
either controls or T0). At T3, six of eight runners showed
higher IL-1RA levels than the upper normal limit of 490 pg/
ml. This increase returned to baseline within 24 h.Fig. 1. Box blots of serum C-reactive protein (CRP) in age-
matched healthy controls (N=16) and marathon runners (baseline
T0, N=8). The upper normal limit (mean plus 2 standard deviations
of 35 healthy controls) is shown by the arrow (left). Serum was
taken during the run (T1, 31 km), at finish (T2, 42 km), after 2 h of
recovery (T3), as well as 24 h (T4) and 48 h (T5) after the run.
Serum levels of CRP were significantly elevated at T4 and T5
(P<0.001, compared with T0, closed stars).Fig. 2. Serum levels of interleukin-1 (IL-1 beta, upper panel) and
interleukin-1 receptor antagonist (IL-1RA, lower panel) in age-
matched healthy controls (N=16) and marathon runners (baseline
T0, N=8). The upper normal limits (means plus 2 standard
deviations of 35 healthy controls) are shown by the arrows (left).
The fluctuations of interleukin-1 did not reach a level of signifi-
cance. In contrast, during (T1, T2) and 2 h after the run (T3), serum
levels of IL-1RA were significantly elevated (P<0.001, compared
with T0, closed stars).INTERLEUKIN-6 AND SOLUBLE INTERLEUKIN-6 RECEPTOR
Concentrations of 0.3 to 19.0 pg/ml IL-6 and 8 to 57 pg/
ml sIL-6R were measured in the serum of healthy individ-uals. In matched controls, medians were 5.8 and 21 pg/ml,
respectively (Fig. 3). At T0, IL-6 was decreased in runners
(median 1.8 pg/ml), while sIL-6R was increased (median
77 pg/ml) (P<0.01 and<0.001, compared with age- and
sex-matched controls). Compared with T0, IL-6 increased
during the run, at T1 and T2 (medians 8.7 and 9.8 pg/ml,
P<0.001 for both), and gradually decreased to baseline
within 24 h (T3, 5.1 pg/ml, P<0.001; T4, 2.2 pg/ml and T5,
2.1 pg/ml, not significant). Considering all samples and
time points (N=83 values), IL-6 correlated with IL-1RA
(r=0.53, P<0.001) and CRP (r=0.29, P<0.01).
Compared with T0, changes in sIL-6R during the run
were not statistically significant. However, levels of sIL-6R,
in contrast to IL-6, were higher than the normal upper limit
of 45 pg/ml, as defined by the mean plus 2 standard
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controls.TUMOR NECROSIS FACTOR- AND SOLUBLE TUMOR NECROSIS
FACTOR RECEPTOR II
Concentrations of 0 to 7.0 pg/ml TNF- and 1955 to
3925 pg/ml sTNFRII were measured in the serum of
healthy individuals. In matched controls, medians of TNF-
and sTNFRII were 3.2 and 2850 pg/ml, respectively (Fig.
4). In runners, baseline serum levels of TNF- and sTNFRII
were significantly elevated (medians 9.7 and 3180 pg/ml,
P<0.02 and 0.01 respectively, compared with matched
controls). Compared with T0, TNF- increased during the
run, at T1 and T2 (medians 16.6 and 14.3 pg/ml, P<0.01
and <0.005), remained elevated 2 h after finish (T3,15.1 pg/ml, P<0.02) and gradually decreased to base-
line within 24 to 48 h (T4 and T5, 13.1 and 10.2 pg/ml,
non significant). From T1 to T3, seven of eight runners
showed higher TNF- levels than the upper normal limit of
10.1 pg/ml.
In contrast to TNF-, concentrations of sTNFRII during
the run remained within the normal limits (up to 3750 pg/ml)
and changes were not statistically significant. Never-
theless, considering all samples and time points (N=83
values), the modest alterations of sTNFRII occurred in
parallel with TNF- (r=0.26, P<0.05).Fig. 3. Serum levels of interleukin-6 (IL-6, upper panel) and soluble
interleukin-6 receptor (sIL-6R, lower panel) in matched healthy
controls (N=16) and marathon runners (baseline T0, N=8). The
upper normal limits (means plus 2 standard deviations of 35
healthy controls) are shown by the arrows (left). At T0 (start), the
serum level of IL-6 was decreased in runners, while the serum
level of soluble IL-6R was increased (P<0.01 and <0.001, open
stars), compared with controls. During the run (T1, T2), the serum
level of IL-6 increased (P<0.001 for both, closed stars) and
gradually decreased to baseline within 24 h (T4). Compared
with T0, changes of sIL-6R during the run were not statistically
significant.Fig. 4. Serum levels of tumor necrosis factor- (TNF alpha, upper
panel) and soluble tumor necrosis factor receptor II (TNFRII/p75,
lower panel) in matched healthy controls (N=16) and marathon
runners (baseline T0, N=8). The upper normal limit of TNF-
(means plus 2 standard deviations of 35 healthy controls) is shown
by the arrow (left). The fluctuations of sTNFRII are found within
normal limits. At T0 (start), the serum levels of both TNF- and
sTNFRII were increased in runners (P<0.02 and 0.01, open stars),
compared with controls. During the run (T1 and T2), the serum
level of TNF- increased (P<0.01 and <0.005), remained elevated
2 h after the run (T3, P<0.02, closed stars) and gradually
decreased to baseline within 24 to 48 h (T4 and T5). Before and
during the run, fluctuations of sTNFRII are measured within normal
limits and were not statistically significant.CARTILAGE OLIGOMERIC MATRIX PROTEIN
Compared with matched controls (median 1.8 g/ml),
serum levels of COMP in runners were increased before
226 M. Neidhart et al.: COMP and MIA in marathon runnersstart (T0, median 7.1 g/ml, P<0.001) (Fig. 5, upper panel).
In six healthy individuals, COMP concentrations between
8–10 am and 3–5 pm showed no significant diurnal vari-
ation (i.e., between −19 and +8%, P=0.89). At T0, baseline
levels of COMP in seven of eight runners were higher than
the upper normal limit of 5.0 g/ml. COMP was significantly
increased in runners, even when compared with the
elevated concentrations in knee joint injury (median 5.7 g/
ml, P<0.01) or OA (median 6.0 g/ml, P<0.05). During the
run, COMP significantly increased (T1, T2 and T3, medians
8.2, 8.8 and 9.1 g/ml, P<0.02 to <0.001). After the run,
COMP returned to baseline within 24 to 48 h (T4, median
7.8 g/ml, P<0.01; and T5, 7.5 g/ml, not significant).MELANOMA INHIBITORY ACTIVITY
Compared with matched controls (median 2.5 ng/ml),
serum levels of MIA in runners were increased before start
(T0, median 7.0 ng/ml, P<0.01) (Fig. 5, lower panel). At T0,
five of eight runners had baseline levels of MIA higher than
the upper normal limit of 6.0 ng/ml. These values were
similar to the elevated levels found in patients with RA
(median 7.5 ng/ml), and higher than the levels observed in
other joint diseases, e.g., OA (median 4.5 ng/ml, P<0.01).
During the run, MIA transiently increased in 3 runners, but
this elevation did not reach a level of significance for the
entire group. MIA was elevated above the upper normal
limit of 6.0 ng/ml in five of eight runners 24 h after the run
(T4) and in six of eight runners at 48 h (T5). Very high
levels were detected in two runners, i.e., 62 ng/ml at T4 and
58 ng/ml at T5.CORRELATIONS
Considering all samples of runners (N=48 values) and
the controls (N=35 values), significant correlation coef-
ficients for COMP could be found with sIL-6R, TNF-,
IL-1RA and sTNFRII (P<0.001 to 0.05) (Table I). For
runners only, evaluating the samples drawn before run (T0,
N=8 values), COMP correlated significantly with sIL-6R
(P<0.05). Considering the samples drawn before, during,
and immediately after the run (T0 to T3, N=32 values),
COMP correlated significantly with IL-1RA (P<0.005).
MIA showed a significant correlation with CRP (P<0.01),
predominantly related to the increase of both CRP and
MIA, 24 and 48 h after the run (Table I). Regarding T0
values, MIA did not correlate with any of the parameter
tested, including COMP. Regarding T0 to T3 values, MIA
negatively correlated with sTNFRII (P<0.005) and sIL-6R
(P<0.01), due to the decrease of MIA from baseline at T2
and T3, and the increases of sTNFRII and sIL-6R during
the same time period.Fig. 5. Serum levels of cartilage oligomeric matrix protein (COMP,
upper panel) and melanoma inhibitory activity (MIA, lower panel) in
matched healthy controls (N=16) and marathon runners (baseline
T0, N=8). The upper normal limits of COMP and MIA (means plus
2 or 3 standard deviations of 35 or 100 healthy controls, respect-
ively) are shown by the arrows (left). At T0 (start), the serum level
of COMP and MIA were increased in runners (P<0.001 and <0.01,
open stars), compared with controls. During the run, COMP
significantly increased (T1 to T3, P<0.02 to <0.001 compared with
T0, closed stars). After the run, COMP gradually returned to
baseline within 24 to 48 h (T4 and T5). During and immediately
after the run (T1 and T2), fluctuations of MIA were not statistically
significant. In five of eight runners, MIA was found to be elevated
24 to 48 h after the run (T4 and T5).Table I
Significant Spearman’s rank correlation coefficients for serum
COMP and MIA in marathon runners (N=8 runners×6 time) and
controls (N=35)
Parameters Significant correlations (r)
All samples and time points pooled (83 values):
COMP sIL-6R 0.69***, TNF- 0.41***, IL-1RA
0.36**, sTNFRII 0.34**
MIA CRP 0.31**
Runner’s baseline (T0, eight values):
COMP sIL-6R 0.61*
MIA No significant correlation
Runners before, during and immediately after the run (T0–T3, 32
values):
COMP IL-1RA 0.41**
MIA sTNRII −0.44**, sIL-6R −0.42**
*P<0.05, **P<0.01, and ***P<0.001.Discussion
In endurance-trained runners, we detected elevated
baseline serum levels (T0) of TNF-, sIL-6R, COMP and
MIA. During the run (T1 and T2), the serum levels of
IL-1RA, IL-6, TNF- and COMP rose significantly. Our
observations confirmed the intensive cytokine response to
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a 5-km run, slight increases in plasma CRP, IL-1RA and
soluble TNF receptors were observed.31 After a 6 h endur-
ance run, increased serum levels of IL-6 and IL-1RA have
been reported,32 associated with decreased mitogen-
stimulated production of IL-1 and TNF- by blood mono-
nuclear cells. Furthermore, 1 h after an exhaustive exercise
stress test (cycling, mean duration 68 min), elevated serum
levels of IL-6 and TNF- were detected.33 At that time, the
mitogen-induced cytokine release by blood mononuclear
cells was suppressed. Thus, it has been concluded that
elevated cytokine levels are present in trained athletes.
Nevertheless, the activation of the immune system, caused
by strenuous exercise is immediately counter-regulated,
e.g., by the release of IL-1RA and TNF receptors.
IL-1RA competes with IL-1 for the same receptor without
having intrinsic activity.34 In our study, serum levels of
IL-1RA progressively increased during the run, with a
maximum at 2 h after the run. A recent study26 reported
post-run increases of IL-1RA mRNA in a few muscle
biopsies and in most blood mononuclear cells. In addition
and according to a previous report,25 serum levels of IL-1
were unchanged, demonstrating that the intensive IL-1RA
response was unrelated to IL-1. On the other hand, as
reported in the same study,25 increased IL-1RA correlated
with serum levels of IL-6.
IL-6 is a multifunctional cytokine produced by a wide
variety of cell types including T lymphocytes, monocyte/
macrophages, fibroblasts, hepatocytes and vascular
endothelial cells. Elevated serum levels of IL-6 have been
reported to be associated with a variety of diseases,
including autoimmune diseases. In patients, serum levels
of IL-6 rose in response to injury, surgery and at an early
stage of acute phase response.35 In runners and according
to previous reports,23,25,26 serum concentrations of IL-6
increased during the runs, with a maximum at finish and a
rapid decrease within hours. The pre-run serum levels of
IL-6 had been low, i.e. within the normal limits. Accordingly,
before the run, IL-6 mRNA could not be detected in muscle
nor in circulating mononuclear cells, whereas after the
run, it was detectable only in muscle biopsies.26 Thus, it
has been suggested that exercise-induced destruction of
muscle fibers may trigger the local production of IL-6,
which in turn might stimulate the production of IL-1RA by
circulating leukocytes.
CRP is an acute-phase protein present in the serum of
healthy individuals at concentrations ranging up to 5 g/ml.
CRP increases significantly in case of inflammation, tissue
damage and necrosis. As IL-6 is considered to be the
mediator of the synthesis of CRP. This process could be
detected in our study by the delayed elevation of serum
CRP, i.e. 24 to 48 h after the run. In runners of the Swiss
Alpine Marathon (Davos, Switzerland, distance 67 km, dif-
ference in altitude 2300 m, mean running time 8.5 h), IL-6,
CRP and creatine kinase were measured before, during
and after the run.36 IL-6 was found to be elevated at the
end of the run. Subsequently, the highest serum levels of
CRP and creatine kinase were found 24 h after the run. In
combination, these results support the hypothesis of a
relation between muscle damage and increased CRP.
A soluble form of the IL-6R (gp80) results from the
proteolytic cleavage of membrane-bound receptors. It has
been suggested that elevated levels of IL-6 might also be
associated with increased production of sIL-6R. Soluble
IL-6R has been shown to bind IL-6 and to enhance the
activity of IL-6 as a result of the binding of the IL-6/sIL-6R
gp80 complex to membrane-bound IL-6R gp130.37,38 Inmarathon runners, baseline serum levels of sIL-6R were
significantly elevated. The modest change of sIL-6R during
the run was correlated with multiple parameters, including
COMP.
TNF- is a pleiotropic cytokine which modulates the
inflammatory and immune reactions occuring in response
to infection or injury. Concentrations of 0.1 to 10.1 pg/ml
TNF- and 700 to 3250 pg/ml sTNFRII are found in the
serum of healthy individuals.
In one study,31 TNF- production decreased after a 5-km
run, showing a minimum at 24 h. In contrast and confirming
previous reports,24,26 in our marathon runners, serum
levels of TNF- were elevated before and rose further
during the run; they remained elevated for 2 h then gradu-
ally decreased to baseline within 24 to 48 h. After the run,
increased TNF- mRNA was found neither in muscle biop-
sies nor in circulating mononuclear cells.26 Therefore, it
must be produced by other cells, e.g., tissue macrophages.
Furthermore, sTNFRII (p75) can neutralize the biological
activity of TNF- by competing with cell surface receptors.
The levels of sTNFRII show inter-individual variations but
are stable for an extended period of time in probates.
Similarly to IL-6 and TNF-, high levels of sTNFRII have
been reported in association with infections; however, the
mechanism involved in the shedding of the TNFRII is not
well understood. Stimuli which cause elevated TNF- levels
can also induce the release of TNFRII. Examining healthy
individuals and our marathon runners, the levels of TNFRII
correlated with TNF-. An increase of soluble TNF recep-
tors (types I and II) in serum has been reported after a 5-km
run.32 In our marathon runners, the baseline levels of
sTNFRII were slightly elevated, but remained within the
normal range. During the run, the concentration of sTNFRII
was stable.
In marathon runners, we found elevated baseline serum
concentrations of two markers which may reflect joint
metabolism and/or damage, namely COMP and MIA. A
previous study39 showed that serum levels of keratan
sulfate, a component of aggrecan, are unchanged in run-
ners before and immediately after a marathon, as well as
48 h later. Patients with joint injury or OA showed elevated
serum levels of both aggrecan and COMP,3,7,13 whereas in
runners these parameters appeared dissociated. Thus, it
has been stated that marathon running causes neither
a transient nor a sustained increase in proteoglycan
catabolism in articular cartilage, therefore showing no
consequence with any pathophysiological process.
COMP is synthesized by chondrocytes or fibroblasts in
articular cartilage, meniscus, tendon and synovial tissue,3–5
and its production may be enhanced by cytokines and
growth factors, e.g., transforming growth factor-1.6 COMP
fragments are present in the serum of healthy individuals at
concentrations ranging up to 5.0 g/ml. Compared with the
elevated serum levels of immunoreactive COMP in trau-
matic joint injury13 or OA,3 the median baseline level of
COMP in marathon runners was similar or even higher.
Thus, before the run, 90% of runners showed COMP levels
higher than the upper normal limit. This may reflect
increased joint matrix molecule turnover and possibly some
joint damage due to extreme physical exercise. It remains
uncertain that any of the markers tested reflect changes
occurring in joints. Nevertheless, in a subgroup of patients
with knee joint injury, persistently elevated serum levels of
COMP for over 2 years may be associated with a risk of
developing OA.13 The rise of COMP serum concentrations
during the run may be indicative of the severe physical
strain on joint structure, but may also be associated with
228 M. Neidhart et al.: COMP and MIA in marathon runnerstendonitis. Considering values of healthy controls and all
the values of the marathon runners, significant correlations
of COMP with sIL-6R, TNF-, IL-1RA and sTNFRII could
be found, suggesting a correlation of COMP with some
aspects of the inflammatory response. Regarding the
samples drawn before and immediately after the run (T0 to
T3), COMP significantly correlated with IL-1RA only, sug-
gesting that in the joint, damages and/or metabolic
changes and the rapid counter-regulation of the inflamma-
tory response occurred simultaneously. The fact that the
highest levels of COMP occurs 2 h after the run suggests
that other factors beside physical strain influence COMP
serum concentrations. One of them could be the kinetics of
lymphatic drainage of synovial matrix molecules from the
joint space to the blood. In addition, exercise could trigger
reactions which persist after cessation, like the creatine
kinase efflux from muscle cells.36
Studies of protein and mRNA levels indicate that MIA is
produced predominantly by malignant melanoma cells and
chondrocytes. In healthy organisms, MIA expression is
thought to be limited to cartilage.16,17 In RA, MIA appears
to be released by chondrocytes during destructive joint
process, and seems only in part due to passive release
from necrotic or apoptotic cells.18 Healthy individuals
showed MIA concentrations in serum ranging from 2.0 to
8.5 ng/ml. MIA values above 6.0 ng/ml are considered
elevated. Elevated baseline MIA concentrations are not
only observed in patients with melanoma15,17 or RA,18 but
also in runners. In three of eight runners, MIA increased
slightly during the run, but the changes were not of statisti-
cal significance. However, in six or seven marathon runners
24 to 48 h respectively after the run, MIA increased to
levels higher than the upper normal limit. The increase of
MIA paralleled the elevation of CRP, suggesting a corre-
lation with late inflammatory processes and—because of
the relationship between CRP and creatine kinase36—
possibly with muscle damage.
For several biomarkers, diurnal variation has been
reported, e.g., for hyaluronan after leaving bed in the
morning.40 Hence, it is important to raise the question
about diurnal rhythms of COMP and MIA. The time of
serum collection from patients and non-running control
subjects was standardized (between 8 and 10 am) to the
time of baseline collection from the runners. Regarding
COMP, no significant difference was observed in six normal
subjects between 8–10 am and 3–5 pm. Therefore, change
in COMP concentrations during the run was not due to a
diurnal variation.
In conclusion, COMP and MIA concentrations increased
most likely due to the extreme physical exertion on joint
structures. However, there is no direct evidence that they
reflect pathological changes occurring in cartilage. COMP
and MIA are released by chondrocytes, but also by other
cell types which might be activated during or after physical
exercise. Thus, considering all the values of the runners
and those of healthy controls, correlation of COMP with
sIL-6R and TNF- suggest joint metabolic changes and
early inflammatory response occurred simultaneously.
COMP also correlated with sTNFRII and the important
IL-1RA response, showing that COMP release coincided
with early counter-regulatory mechanisms. MIA and CRP
increased within 24 h after the run, but the nature of the
correlation is yet unclear. All in all, our data suggest a more
complex regulatory mechanism than the passive release of
matrix proteins from articular cartilage due to joint damage.
The kinetics of COMP and MIA suggest different triggering
mechanisms and/or sources, i.e. either tendon, meniscus,synovial fibroblasts or chondrocytes. Since COMP and MIA
fluctuations correlated with different phases of the run and
the recovery, they are potential markers of different aspects
of joint matrix turnover and/or damage in both rheumatic
diseases and sport.Acknowledgments
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